Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol.
Ikuko HiraiKeiji TaneseKeitaro FukudaTakayuki FusumaeYoshio NakamuraYasunori SatoMasayuki AmagaiTakeru FunakoshiPublished in: Medicine (2022)
NCT04546074. Date of Registration: September 11, 2020 (https://clinicaltrials.gov/ct2/show/NCT04546074). Date of First Participant Enrollment: December 23, 2020.
Keyphrases
- study protocol
- chronic myeloid leukemia
- randomized controlled trial
- clinical trial
- computed tomography
- open label
- phase iii
- image quality
- dual energy
- advanced non small cell lung cancer
- contrast enhanced
- phase ii
- magnetic resonance imaging
- wild type
- magnetic resonance
- stem cells
- placebo controlled
- epidermal growth factor receptor
- affordable care act
- skin cancer
- bone marrow